Navigation Links
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Date:10/25/2007

- Third Trial to Utilize FDG-PET Imaging -

SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will soon initiate a third Phase II clinical trial for VIA-2291, its lead compound. VIA-2291 targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The new trial design utilizes Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET) to measure the impact of VIA-2291 on reducing vascular inflammation in treated patients.

The Company plans to enroll approximately 50 patients following an acute coronary syndrome event into a 24 week randomized, double blind, placebo- controlled study. Endpoints in the study will include reduction in plaque inflammation as measured with FDG-PET, as well as assessment of standard biomarker measurements of inflammation.

VIA is collaborating on the study with Michael Farkouh, M.D. and Zahi Fayad, Ph.D. of Mount Sinai Heart in New York City, and Ahmed Tawakol, M.D. of Massachusetts General Hospital in Boston.

"VIA-2291 could provide a novel approach to addressing inflammation in coronary artery disease," said Adeoye Olukotun, MD, chief medical officer of VIA. "This trial is an excellent example of utilizing the benefits of new imaging technology to help accelerate the development of potentially break- through drugs. The use of state-of-the art FDG-PET imaging technology provides an ideal methodology for measuring the effect of VIA-2291 on reducing vascular inflammation in atherosclerosis."

L
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
(Date:2/27/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is ... Conference on March 10 in Miami Beach ... vice president and chief financial officer, and Susie ... a 25-minute question and answer session regarding the company ... Following a 5-minute break, a question and answer session ...
(Date:2/27/2015)... MISSISSAUGA, ON , Feb. 27, 2015 /CNW/ - Covalon ... advanced medical technologies company, today announced financial results for ... For the three months ended December 31, 2014, ... for the quarter was $229,820 or $0.02 per share.  ... Pedlar , said "I am very pleased with the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:2/28/2015)... 2015 In recent years Medical Marijuana has ... physicians as a way for them to expand their patient ... as medicine. Since the FDA still lists Cannabis as a ... to licensed physicians that can help guide them when ... Malka in Santa Cruz, CA is a leader in ...
(Date:2/28/2015)... With their commitment to achieving physical results ... exercise to their already robust library of oblique exercises. ... known as, is often performed on a stationary piece ... a relatively safe manner and can be performed by ... description of “Rope Pulls” is located in the oblique ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... are better. A study of a tropical wasp suggests ... , University of Washington researchers have found that key processing ... one wasp species not only increased in size with age ... also showed different patterns of brain development in males and ...
... Holmes,Inc. (Amex: HH ) today announced that it ... before market on Friday, March 14, 2008.,The Company will ... at,11:00am EDT., Conference Call, To participate in ... code: Hooper Holmes. A live web cast will be ...
... growth, has shown promising results as a potential therapeutic ... its inhibition led to increased muscle mass and strength. ... inhibitor in patients, assessed its safety in adults with ... study was published today in Annals of Neurology ( ...
... County to house world class research, center in country,s Indianapolis region, ... medicine into mainstream ... practice, ... joined by Indiana Gov. Mitch Daniels, broke,ground today on its $140 million ...
... YORK, March 11 HMS Holdings Corp.,(Nasdaq: HMSY ... Bank Of America,2008 SmidCap Conference, which will be held ... Walter Hosp, Chief Financial Officer of HMS Holdings Corp., ... HMS Holdings Corp. (Nasdaq: HMSY ) is ...
... aggravate existing problems, ... CEOs say, ... to reject a proposal to,eliminate the state,s planning process for new hospitals, ... in,funding to care for the elderly and poor, and already grappling with,serious ...
Cached Medicine News:Health News:Which came first, social dominance or big brains? Wasps may tell 2Health News:Which came first, social dominance or big brains? Wasps may tell 3Health News:Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information 2Health News:New potential treatment for muscular dystrophy appears to be safe 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 3Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 4Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 5Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 2Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 3
Disposable or reusable AEM cord for use with 5mm AEM Laparoscopic Instruments ....
... Wolf offers protection ... exceptional shielding values with ... high optical quality. Lenses ... equivalency and are anti-reflection ...
... our coat apron, weight is distributed ... of comfortable wear without fatigue. Made ... our front closing special procedure apron ... closures that make it a cinch ...
The O.R. Special Protective Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is availa...
Medicine Products: